Background. Classic modeling of sexually transmitted diseases has focused on modeling behavioral heterogeneity and designing epidemic control strategies targeted at behavioral core groups.
and transmission can occur only when individuals are shedding virus. Most transmissions occur during subclinical episodes of viral reactivation. There is great heterogeneity in the frequency of reactivation; some infected individuals experience frequent viral reactivation events, whereas others experience viral reactivation only rarely [4] [5] [6] [7] [8] . Daily antiviral therapy (DAT) has been shown to markedly reduce the frequency of HSV-2 reactivation among both men and women [6, 7, 9] . More recently, in HSV-2-infected individuals, DAT with valacyclovir has been shown to reduce transmission of HSV-2 among monogamous sex partners by ∼50% [10] . Although valacyclovir has received approval from the US Food and Drug Administration for its use in preventing the transmission of genital herpes, it is unclear what public health effect DAT could have on reducing incidence rates of HSV-2, because the majority of HSV-2-infected individuals are asymptomatic [1] [2] [3] and are therefore unlikely to have the infection diagnosed and to be offered DAT.
Classic modeling of sexually transmitted diseases has focused on modeling behavioral heterogeneity and on designing epidemic control strategies targeted at behavioral core groups [11, 12] . This modeling approach is sensible when there is little biological heterogeneity in disease pathogenesis. Under these conditions, high-frequency transmitters are characterized by their high numbers of new sex partners, and behavioral core groups contribute disproportionately to the transmission rate [11, 12] . Because there is no cure for HSV-2 infection, all individuals infected with HSV-2 remain infected for life, but, because of the variation in reactivation rates over time in any 1 individual and because of the heterogeneity in reactivation rates between individuals, there is considerable variability in the amount of time that an individual will be infectious. Infected individuals with a high frequency of reactivation shed virus on a high proportion of days and hence have the potential to cause substantially more HSV-2 infections than infected individuals with a low frequency of reactivation. Hence, the high-frequency transmitters in HSV-2 epidemics are likely to be individuals with high rates of viral reactivation. Thus, we hypothesized that targeting virological core groups (i.e., individuals with high rates of viral reactivation) would be an effective new strategy for controlling HSV-2 epidemics. Here, we present a novel mathematical model of HSV-2 epidemics that includes virological core groups. We used this model in conjunction with virological data to address 2 questions: first, what is the role of virological core groups in contributing to HSV-2 transmission? and, second, if virological core groups were targeted for treatment, what effect would suppressive antiviral therapy have on reducing transmission? We quantified the role of virological core groups in contributing to HSV-2 transmission by using data to estimate the value of the basic reproduction number of HSV-2 (R 0 ), where R 0 is defined as the average number of secondary infectious cases of HSV-2 that are produced by 1 infectious individual introduced into a population in which everyone is susceptible and no treatment is available [13, 14] . We then predicted the potential public health effect of targeting virological core groups, by estimating both the potential population-and individual-level effectiveness of DAT in reducing transmission. We determined population-level effectiveness by using data to estimate the value of R, where R is defined as the case reproduction number of HSV-2 when treatment is available [13, 14] , and by calculating the average number of HSV-2 infections prevented by DAT over time. We determined individual-level effectiveness by calculating the number of person-years of DAT that would be necessary to prevent 1 HSV-2 infection. Finally, we discuss the implications of our results for designing new and effective epidemic control strategies.
METHODS
Virological core group model. Our virological core group model depicts the transmission dynamics of HSV-2 in a sexually active population and builds on our earlier models of HSV-2 epidemics [14] [15] . A flow diagram of the model is shown in figure 1 , where the superscript modifier signifies the viral reactivation rate of the infected individual (H, high viral reactivation rate; L, low viral reactivation rate; and S, suppressed viral reactivation rate due to DAT). Infected individuals oscillate between 2 states: viral shedding, when they are infectious but can be either asymptomatic or symptomatic, and quiescent, when the virus is latent, and, hence, infected individuals are noninfectious. The viral reactivation rate (r) is the rate per capita at which viruses reactivate from the quiescent state (when they are sequestered in the dorsal ganglia), travel via neurons to the genital mucosa, and begin shedding. The average length of the viral shedding episode is specified by 1/q and is exponentially distributed. Thus, the average length of time during which an individual is infectious and has the potential to transmit HSV-2 can be calculated by multiplying 1/q by the total number of viral reactivation episodes that occur during the individual's sexual life span, which is defined as the time over which an individual acquires new sex partners [13, 14] .
To model heterogeneity in rates of viral reactivation, we modeled 3 types of infected individuals and also included temporal waning in rates of viral reactivation. We modeled "high-frequency shedders" (who always have high rates of viral reactivation during their sexual life span), "low-frequency shedders" (who always have low rates of viral reactivation during their sexual life span), and "high-to-low-frequency shedders" (who have high rates of viral reactivation when they are first infected with HSV-2 but wane to lower rates of viral reactivation during their sexual life span at rate q [i.e., the number of days that they are infectious per year decreases over time]) (figure 1). At any particular time, high-frequency shedders and high-to-lowfrequency shedders (when they have high reactivation rates) constitute the virological core group (figure 1). Low-frequency shedders and high-to-low-frequency shedders (when they have low reactivation rates) constitute the virological noncore group (figure 1). It is important to note that the virological core group is the minority group and is not simply the group of newly infected symptomatic persons who have high shedding rates for the first year after acquiring infection. The equations that specify our mathematical model are as follows:
dt where and
)/NN. We modeled different treatment strategies using current medical guidelines for antiviral therapy; hence, we allowed highfrequency shedders to receive either episodic therapy (i.e., they could receive treatment only during a viral shedding episode) or DAT (figure 1). Individuals receiving DAT continued to receive therapy for a specified duration; during this time, their viral reactivation rate was reduced, but episodic outbreaks could occur infrequently (figure 1). Low-frequency shedders were eligible only for episodic therapy, and high-to-low-frequency shedders could receive episodic therapy or DAT (when they were high-frequency shedders), but only episodic therapy once their viral reactivation rate waned and they became low-frequency shedders (figure 1). Therefore, individuals in the virological core group were eligible for either episodic therapy or DAT, and individuals in the virological noncore group were eligible only for episodic therapy. The model structure also allowed HSV-2-infected individuals to start and stop receiving episodic therapy and DAT at any time and individuals with both prevalent and incident cases to receive either therapy.
Monte Carlo estimates of R 0 , R, and cumulative infections prevented. We analyzed our model to derive an analytical expression for R 0 and R [13, 14] . R 0 and R are threshold conditions used to evaluate both the severity of an epidemic and the control measures that are necessary to reduce ( ) and/ R 1 R 0 or eradicate ( ) the pathogen; thus, the ratio (
indicates the degree to which treatment would reduce the severity of the epidemic. During an ongoing HSV-2 epidemic, persons infected with HSV-2 are not at risk of reinfection; thus, another reproduction number can also be calculated (R , the effective reproduction number). R is defined as the average number of secondary infectious cases of HSV-2 that are produced by 1 infectious individual over time; hence, R p R 0 x(t), if no treatment is available, or , if treatment is avail-R p Rx(t) able, where x(t) specifies the fraction of the population who are susceptible at time t. At the start of an epidemic, everyone is susceptible; hence, , and , if no treatment is
, if treatment is available. As the epidemic R p R progresses and prevalence increases, x(t) and R decrease until a steady-state equilibrium is reached, at which point , R p 1 and , if no treatment is available, or , if treat-
ment is available. If treatment levels are sufficient to cause , then R will decrease to 0. It is important to note that R ! 1 all of the reproduction numbers are related to each other; however, R 0 and R are time independent, whereas R is time dependent because it varies as a function of x(t). Thus, R 0 and R are often more useful measures than R .
We estimated the values of R 0 and R by using parameter estimates obtained from virological data and stochastic simulations based on Monte Carlo methodology [16, 17] . We also used Monte Carlo methods to conduct a time-dependent uncertainty and multivariate sensitivity analysis of the cumulative number of infections prevented over time (a time-dependent measure related to R ) [16, 18] and the number of personyears of DAT that would be necessary to prevent 1 HSV-2 infection. By use of a Monte Carlo sampling technique, we were able to simultaneously vary the values of all of the input parameters, each of which was specified by a probability density function (pdf). To conduct the time-dependent uncertainty analysis, we numerically simulated the model 1000 times by use of a Latin hypercube sample of the parameter space; computer programs were written in C. We conducted multivariate sensitivity analysis of all outcome variables and calculated sensitivity coefficients in terms of partial rank correlation coefficients (PRCCs) [16] [17] [18] . We used virological data sets to estimate the pdfs for each model parameter and then used Monte Carlo sampling to sample from these pdfs (table 1) . We used data on the average number of viral-shedding episodes per year and on the average length of an infectious episode (pdfs given in table 1) to estimate average rates of viral reactivation for both the high-frequency shedders and the low-frequency shedders [13, 14] . We predicted the potential public health effect of increased usage of DAT by using Monte Carlo methods to conduct a time-dependent uncertainty analysis [16, 18, 26] . Treatment parameters in the model were used as exploratory variables by specifying pdfs [18, 26] . We assumed that, at any point in time, 10%-90% (with a likely value of 50%) of the virological core group could receive DAT, individuals would receive DAT for 6 months to 5 years (with a likely value of 2 years), and DAT would be 70%-95% effective in suppressing viral reactivation in high-frequency shedders. These latter figures are based on published data on the effectiveness of DAT [27] , as measured by detection of mucosal HSV DNA by use of polymerase chain reaction and by data from pharmaceutical companies on the average duration of DAT once it is initiated. In addition, we assumed that a median of 3% (interquartile range [IQR], 1%-5%) of high-frequency shedders and 9% (IQR, 4%-15%) of low-frequency shedders would receive episodic therapy.
RESULTS
Our 1000-sample Monte Carlo data-sampling procedure generated parameter values for both virological core groups and noncore groups; the relative sizes of the groups varied in each of the 1000 simulations, but the core group always contained the fewest individuals. We calculated the average number of days that an individual shed virus per year in each group ( figure   2A ). Infected individuals in the core group with the highest reactivation rate had an average of 94 (25.8%) viral shedding days (VSDs)/year, and infected individuals in the core group with the lowest reactivation rate had an average of only 20 (5.5%) VSDs/year (figure 2A). In contrast, infected individuals in the noncore group with the highest reactivation rate had an average of 39 (10.7%) VSDs/year, and infected individuals in Figure 3 . Graphical results of multivariate sensitivity analysis using analytical expression for case reproduction number (R). A, Percentage reduction in R due to the effectiveness of daily antiviral therapy (DAT) in reducing viral reactivation in high-frequency shedders. B, Percentage reduction in R due to increasing the duration of DAT (X-axis) and increasing the coverage of the virological core group; the lower curve of the colored region specifies the lower bound when 10% of the virological core group receive DAT, and the upper curve specifies the upper bound when 90% of the virological core group receives DAT. C, Percentage reduction in R due to increasing the coverage of the virological core group (X-axis) and increasing the duration of DAT; the lower curve of the colored region specifies the lower bound when the average duration of DAT is 6 months, and the upper curve specifies upper bound when the average duration of DAT is 5 years.
the noncore group with the lowest reactivation rate had an average of only 8 (2.2%) VSDs/year (figure 2A). We used the viral-shedding data and the derived analytical expression for R 0 to calculate Monte Carlo estimates of R 0 . Mathematical analyses of our model equations revealed that R 0 p pR HLR is the basic reproduction number in the high-to-low-frequency shedders, and R 0 LR is the basic reproduction number in the low-frequency shedders. The detailed expression for R 0 (derived from our model) is as follows:
We used our data to estimate that the value of R 0 (as calculated with equation 8) was 1.3-2.0; these values give a population prevalence of HSV-2 infection of 22%-50%, a figure supported by several serological surveys of HSV-2 seroprevalence in North America and Europe [1, 3] . We used our model to calculate the relative contributions of the virological core and the noncore groups to the value of R 0 . An average individual in the virological core group generates more secondary HSV-2 infections than does an average individual in the noncore group (figure 2B). If 22% of the population is infected with HSV-2 (as in the general population in the United States [1] ), then our model predicts that an individual in the virological core group generates a median of 1.6 secondary infections (IQR, 1.5-1.7 secondary infections) and that an individual in the noncore group generates a median of only 1.1 secondary infections (IQR, 1.0-1.2 secondary infections) ( figure 2B, blue data) . At higher HSV-2 prevalence rates (e.g., 50%, such as in certain African American and gay communities in the United States [1, 3] ), the difference in R 0 between the core and the noncore groups is more substantial; under these conditions, an average individual in the core group generates a median of 2.5 secondary infections (IQR, 2.3-2.7 secondary infections), whereas an average individual in the noncore group generates a median of 1.7 secondary infections (IQR, 1.6-1.8 secondary infections) ( figure 2B, red data) . In terms of the overall contribution to R 0 , we calculated that individuals from the virological core group cause a median of 44% of new HSV-2 infections (IQR, 36%-52% of new HSV-2 infections), even though the core group constitutes only a small proportion (median, 11%; IQR, 8%-14%) of the infected population; thus, individuals in the virological core group have a disproportionate effect in driving the epidemic. We used our model to examine the potential effects of DAT on transmission dynamics. We determined the effect of DAT on reducing R and on preventing HSV-2 infections. We used virological data (see Methods) to obtain Monte Carlo estimates of R. For an epidemic with a prevalence of 22%, we calculated that R would be reduced to !1 (median, 0.86; IQR, 0.78-0.94) and that, hence, R would tend toward 0; however, if the initial prevalence of the HSV-2 epidemic was 50%, then R would remain 11 (median, 1.34; IQR, 1.21-1.46). It should be noted that, since , HSV-2 prevalence will decrease over time and, hence, x R ! R 0 will increase; thus, R is not simply prevalence). R ϫ (1 Ϫ current Our results imply that any strategy directed at interrupting transmission among infected persons (such as DAT) could eventually lead to eradication of HSV-2 epidemics if prevalence was !25%, although eradication would take many decades. However, if the pretreatment prevalence was 125%, eradication would not occur, but transmission would be reduced.
We used multivariate sensitivity analysis to identify the key determinants in treatment strategies that would be the most effective in reducing epidemic severity (i.e., in reducing R) ( figure 3 ). The effectiveness of DAT in reducing the viral reactivation rate was the most important treatment parameter ( ). As the effectiveness of DAT in suppress-PRCC p Ϫ0.85 ing reactivation episodes in high-frequency shedders increased from 70% to 95%, the reduction in R increased substantially, from 8% to 61% (with a median reduction of 33%) ( figure   3A ). The second key determinant in reducing epidemic severity was the degree of coverage of DAT in the virological core group. As the fraction of the virological core group receiving DAT increased from 10% to 90%, the reduction in R increased (PRCC p Ϫ0.49) ( figure 3C ). However, it is noteworthy that the average duration of DAT (range, 6 months to 5 years) was relatively unimportant in reducing R ( ) ;t h e PRCC p Ϫ0.25 duration of DAT was found to be important only if the coverage of DAT in the virological core group was very low (figure 3B). These results show that, to reduce the epidemic of HSV-2, it would be more effective to have a larger fraction of the virological core group receiving DAT for a short time than to have a smaller fraction of the virological core group receiving DAT for a long time. This is because the reduction in transmission is determined by the total number of individuals receiving DAT at any point in time; thus, the coverage rate of the virological core group is more important than the duration of DAT.
Next, we determined population-level effectiveness of DAT by calculating the cumulative number of HSV-2 infections prevented over time ( figure 4A ; red data, 50% HSV-2 prevalence; blue data, 22% HSV-2 prevalence). The disproportionate population-level effect of targeting the virological core group is readily apparent. By treating only a relatively small percentage of individuals, it would be possible to prevent a substantial number of new HSV-2 infections (figure 4A). After only 1 year, a median of 25% (IQR, 19%-32%; minimum, 7%; maximum, 56%) of HSV-2 infections would be prevented ( figure 4A ). Population-level effectiveness will be variable and will depend on the degree of coverage of DAT; the greater the coverage of DAT, the greater the number of HSV-2 infections prevented ( figure 4A ). High-prevalence HSV-2 epidemics (50% prevalence) will likely require substantially higher coverage than will moderate-prevalence epidemics (22% prevalence), to achieve a comparable reduction in incidence (figure 4A), because DAT reduces R to !1 if the initial HSV-2 prevalence is 22%, but R remains 11 if the initial HSV-2 prevalence is 50%. Finally, we determined the potential individual-level effectiveness of DAT by calculating the number of person-years of DAT that would be necessary to prevent 1 HSV-2 infection (figure 4B). Our results show that 1 HSV-2 infection would be prevented for every 6.4 person-years (IQR, 5.1-8.1 person-years) of DAT. Therefore, even if DAT is not widely used, it would not be hard to prevent HSV-2 infections if individuals in the core group with high viral shedding rates are targeted.
DISCUSSION
Our modeling results provide several novel insights into the transmission dynamics of HSV-2 epidemics. By analyzing virological data with our new theoretical framework, we have found that the biological variability in the viral-shedding patterns (between and within individuals) markedly influences the transmission dynamics of genital herpes. Although we are not suggesting that shedding frequency is the sole determinant in influencing transmission dynamics (obviously, other host genetic and virological factors are also important), we do suggest that patterns of viral shedding are likely to explain some of the varied prevalence rates in HSV-2 seen in populations worldwide. Our results indicate that the majority of new HSV-2 infections that occur may be attributable to a relatively small percentage of persons who are high-frequency shedders. The model that we formulated allows a single individual to move from the virological core group (high-frequency shedders) to the noncore group (low-frequency shedders) over time. Thus, our model reflects data from many empirical studies showing that individuals with recently acquired genital herpes almost always shed virus at high rates (125% of days) for the first few months after acquisition of infection, whereas only a small fraction of persons who have longstanding genital herpes (110 years) shed HSV-2 at such rates. Our results suggest that identifying persons with incident genital herpes and utilizing DAT may be a new strategy to consider for public health control. Our results indicate the importance of implementing effective control programs before prevalence increases to 150%. Of interest, our results demonstrate that identifying and treating (for a short period of time) a high percentage of high-frequency shedders would be more effective in reducing transmission than would treating fewer persons for a long period of time.
Valacyclovir has recently been shown to reduce the transmission of HSV-2 among sex partners and is a new case-management tool for physicians [10] . Valacyclovir could also potentially act as a public health prevention tool. Our modeling analyses suggest that HSV-2 could be reduced by concentrating on identifying and treating persons who have high-frequency HSV-2 reactivation. We have shown both that virological core groups are extremely important in transmission and that targeting virological core groups could be effective in reducing transmission. Conventional control strategies for sexually transmitted diseases are based on targeting behavioral core groups [11, 12] . Because HSV-2 is very prevalent (120% in the general population), targeting behavioral core groups will be ineffective in controlling genital herpes. We suggest that virological core groups should be targeted for treatment; the virological core group that we have defined includes people who are high-frequency shedders. Unfortunately, to date, only frequent sampling of mucosal sites can identify (on an individual basis) high-frequency shedders. Automated methods to detect HSV shedding from frequent sampling are now available, and it is possible that technological breakthroughs may afford even more cost-effective approaches. At present, the best epidemiological determinant of a high-frequency shedder is recent acquisition of genital herpes (i.e., persons infected during the last 12-18 months) [4, 28] . In the United States and Europe, the majority of the virological core group members are therefore likely to be sexually active adults in their mid-20s.
Recent theoretical analyses have shown that antiretrovirals could decrease transmission of HIV [18, 26, 29, 30] ; however, to achieve a significant reduction in incidence rates, a large percentage of HIV-infected individuals need to receive treatment [18, 26, 29, 30] . In contrast, one of the attractive features of our proposed new strategy for HSV-2 epidemics is that only a relatively small fraction of HSV-2-infected individuals would need to be treated to substantially reduce HSV-2 transmission. Clinical studies have indicated that almost all high-frequency shedders are symptomatic [31] [32] [33] . Although many of these individuals have unrecognized disease because of nonspecific symptoms or previous misdiagnosis of genital herpes, recent studies have shown that serological assays can accurately identify such persons [34, 35] . Applying Bayesian statistical analyses to virological data can be used to quantify the rate of waning of rates of viral reactivation of high-frequency shedders [36] . The feasibility of identifying members of the virological core group needs to be examined, and their adherence to antiviral therapy assessed. However, because of their symptoms, many members of the virological core group are likely to seek and comply with treatment. Studies have shown that compliance with anti-herpes virus therapy among persons with recognized symptomatic diseases is high [37, 38] . Individuals who are most in need of the therapeutic benefits of DAT are also those whom it is most important to target for prevention (i.e., "super shedders" are likely to be "super spreaders"). In summary, targeting virological core groups would be both a potentially effective and practical novel public health strategy for interrupting the transmission of genital herpes with current therapeutic tools. Because HSV-2 epidemics fuel HIV epidemics [39] , our proposed strategy for reducing HSV-2 epidemics could also potentially reduce HIV transmission in certain locations.
